Evidence map›Paper›PMID 30099006›Full record

ArticleBiochemical pharmacology2018

Selective up-regulation of cannabinoid CB

Susana Mato, Fuencisla Pilar-Cuéllar, Elsa M Valdizán, Javier González-Maeso, Rafael Rodríguez-Puertas, Javier Meana, Joan Sallés, Benedicto Crespo-Facorro, Ángel Pazos

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Chronic Pain and Opioids in the Elderly: Treating the Brain, Not Just the Body.International journal of environmental research and public health · 2026
    Review
  2. CB1R activates the epilepsy-associated protein Go to regulate neurotransmitter release and synaptic plasticity in the cerebellum.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Susana MatoDepartment of Physiology and Pharmacology, University of Cantabria, E-39011 Santander, Spain.
Fuencisla Pilar-CuéllarDepartment of Physiology and Pharmacology, University of Cantabria, E-39011 Santander, Spain; Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), E-39011 Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), E-28029 Madrid, Spain.
Elsa M ValdizánDepartment of Physiology and Pharmacology, University of Cantabria, E-39011 Santander, Spain; Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), E-39011 Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), E-28029 Madrid, Spain.
Javier González-MaesoDepartment of Pharmacology, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.
Rafael Rodríguez-PuertasDepartment of Pharmacology, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.
Javier MeanaCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), E-28029 Madrid, Spain; Department of Pharmacology, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.
Joan SallésCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), E-28029 Madrid, Spain; Department of Pharmacology, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.
Benedicto Crespo-FacorroCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), E-28029 Madrid, Spain; Hospital Universitario Marqués de Valdecilla, University of Cantabria-IDIVAL, School of Medicine, Department of Psychiatry, Santander, Spain.
Ángel PazosDepartment of Physiology and Pharmacology, University of Cantabria, E-39011 Santander, Spain; Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), E-39011 Santander, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), E-28029 Madrid, Spain. Electronic address: pazosa@unican.es.
Centro de Investigación Biomédica en Red de Salud Mental · ESUniversity of the Basque Country · ESInstituto de Biomedicina y Biotecnología de Cantabria · ESMarqués de Valdecilla University Hospital · ESUniversidad de Cantabria · ES

Funding

Structure and function of the 5HT2A/mGluR2 complex in schizophreniaR01MH084894 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI Javier Gonzalez-Maeso · 2009 to 2026
$6.8M
Preclinical role of HDAC2 in mGlu2-dependent schizophrenia treatmentR01MH111940 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI GONZÁLEZ-MAESO, JAVIER · 2017 to 2021
$1.5M
NIMH NIH HHS R01 MH084894NIMH NIH HHS R01 MH111940
6 · The paper itself

Abstract

Brain endocannabinoid system is proposed to play a role in the pathogenesis of affective disorders. In the present study, we analyzed the functionality of the cannabinoid receptor type 1 (CB

Indexed as

SuicideAdenylyl CyclasesAdultAgedAged, 80 and overFemaleGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gi-GoGuanosine 5'-O-(3-Thiotriphosphate)HumansMajor Depressive DisorderMaleMiddle AgedPrefrontal CortexReceptor, Cannabinoid, CB1Up-RegulationAdenylyl CyclasesCNR1 protein, humanGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gi-GoGuanosine 5'-O-(3-Thiotriphosphate)Receptor, Cannabinoid, CB1Adenylyl cyclaseCB(1) receptorsGα subunitsMajor depressionPrefrontal cortex

Identifiers

PMID30099006
PMCPMC6263149
OpenAlexW2885767664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.